Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180869 | 1.00 | EGLN1 (0.35) | EGLN1THRAVDRCCR5ALDH1A1 | |
| SCHEMBL14142023 | 0.90 | EGLN1 (0.35) | EGLN1THRAVDRCCR5ALDH1A1 | |
| SCHEMBL10179775 | 0.88 | TLR7 (0.39) | ALDH1A1MAPT | |
| SCHEMBL10179508 | 0.88 | STAT3 (0.34) | EGLN1CCR5GUCY1A1GUCY1B1SLC18A3 | |
| SCHEMBL10179510 | 0.88 | STAT3 (0.34) | EGLN1CCR5GUCY1A1GUCY1B1SLC18A3 | |
| SCHEMBL10181122 | 0.87 | EGLN1 (0.37) | EGLN1GUCY1A1GUCY1B1 | |
| SCHEMBL10179177 | 0.81 | EGLN1 (0.34) | EGLN1ALDH1A1 | |
| SCHEMBL14142016 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1MAPT | |
| SCHEMBL10179375 | 0.78 | CCR5 (0.34) | EGLN1THRAVDRCCR5GUCY1A1 | |
| SCHEMBL10179503 | 0.77 | PPARG (0.40) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | EGLN1 1443/4885THRA 413/4885VDR 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.